Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome

a study on WHIM Syndrome

Summary

Eligibility
for people ages 12 years and up (full criteria)
Location
at San Diego, California and other locations
Dates
study started
estimated completion
Principal Investigator
by Bob Geng, MD

Description

Summary

This study has a double-blind, placebo-controlled Randomized Period and an Open-Label extension Period. The primary objective of the Randomized Period is to demonstrate the efficacy of mavorixafor in participants with WHIM syndrome as assessed by increasing levels of circulating neutrophils compared with placebo, and relative to a clinically meaningful threshold. The primary objective of the Open-Label Period is to evaluate the safety and tolerability of mavorixafor in participants with WHIM syndrome. Participants are allowed to continue treatment in the Open-Label extension Period, if regionally applicable, until mavorixafor becomes commercially available, or until the study is terminated by the Sponsor.

Official Title

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients With WHIM Syndrome With Open-Label Extension

Keywords

WHIM Syndrome Syndrome Mavorixafor

Eligibility

You can join if…

Open to people ages 12 years and up

  • Have signed the current approved informed consent form. Participants under 18 years of age (in the Netherlands and other applicable regions, participants under 16 years of age) will sign an approved informed assent form and must also have a signed parental/legal guardian consent.
  • Have a genotype-confirmed mutation of chemokine (C-X-C motif) receptor 4 (CXCR4) consistent with WHIM phenotype.
  • Agree to use a highly effective form of contraception.
  • Be willing and able to comply with the protocol.
  • Have confirmed ANC ≤400 cells/µL during screening, obtained while participant has no clinical evidence of infection.

Inclusion Criteria for the Open-Label Period:

  • Completed the Randomized Period; or
  • Granted Early Release from the Randomized Period.

You CAN'T join if...

  • Has known systemic hypersensitivity to the mavorixafor drug substance, its inactive ingredients, or the placebo.
  • Is pregnant or breastfeeding.
  • Has any medical or personal condition, which in the opinion of the Investigator may potentially compromise the safety or compliance of the participant or may preclude the participant's successful completion of the clinical study.

Exclusion Criteria for the Open-Label Period:

  • Participants who experience any treatment-limiting toxicity (TLT) will be excluded from participating in the Open-Label Period.

Locations

  • University of California San Diego Health/Rady Children's Hospital accepting new patients
    San Diego California 92123 United States
  • California Dermatology Institute accepting new patients
    Thousand Oaks California 91320 United States

Lead Scientist at UCSD

  • Bob Geng, MD
    Assistant Clinical Professor, Medicine. Authored (or co-authored) 8 research publications.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
X4 Pharmaceuticals
ID
NCT03995108
Phase
Phase 3
Study Type
Interventional
Last Updated
Contact us about this trial